Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy

NCT04605146 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT04605146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04605146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy
Lead sponsor
Hospices Civils de Lyon
Phase
Not applicable
Overall status
Recruiting
Start date
May 5, 2021
Completion date
November 5, 2028
Enrollment
100 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, melanoma, renal cancer